Diabetic nephropathy is the most common cause of end stage renal failure (ESRF) in the developedof world and as the incidence of diabetes increases this trend will continue, although most of these patients will die of cardiovascular diseases. The renin-angiotensin system (RAS) is believed to play a central role in the development and progression of both micro- and macrovascular complications of diabetes and blocking this system in diabetic patients is critically important. Two widely used inhibitors of RAS are angiotensin-converting enzyme (ACE) inhibitors and angiotensin receptor blockers (ARBs). These drugs affect the system at different levels and thus may have an additive effect. Use of drugs from one class may not be completely effective in blocking this system for several reasons. In this article we discuss issues surrounding the use of dual blockade (i.e. the use of ARB and ACE inhibitors together in patients with diabetic nephropathy responding insufficiently to previous antihypertensive treatment including either ARB or ACE inhibitors) in patients with diabet
Ritz E., Rychlik I., Locatalli F., Halami S.End stage renal failure in type 2 diabetes: a medical catastrophe of worldwide dimensions. Am J Kidney Dis1999 ;34:795-808.
2.
Laakso M.Hyperglycaemia and cardiovascular disease in type 2 diabetes. Diabetes1999;48:937-42.
3.
United Kingdom ProspectiveDiabetes Study Group.Intensive blood glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes. UKPDS 33. Lancet1998;352:837-53.
4.
United Kingdom Prospective Diabetes Study Group.Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. BMJ;317:703-13.
5.
Angélique ME , Spoelstra-de Man Catherine B., et al. Rapid Progression of Albumin Excretion Is an Independent Predictor of Cardiovascular Mortality in Patients With Type 2 Diabetes and Microalbuminuria. Diabetes Care2001;24:2097-101.
Williams B., Poulter N., Brown M. et al. British Hypertension Society guidelines for hypertension management 2004 (BHS-IV): summary. BMJ2004; 328:634-40.
8.
Rosner MH, Okusa MDCombination therapy with angiotensin-converting enzyme inhibitors and angiotensin receptor antagonists in the treatment of patients with type 2 diabetes mellitus . Arch Intern Med2003 ; 163:1025-9.
9.
Tomlinson JW , Owen K., Close CFTreating hypertension in diabetic nephropathy . Diabetes Care2003;26:1802-05.
10.
Winocour PHEffective diabetes care: a need for realistic targets. BMJ2002;324:1577-80.
11.
Elliott WJTherapeutic trials comparing angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers. Curr Hypertens Rep2000; 2:402-11.
12.
Lewis EJ, Hunsicker LG, Bain RP et al. for The Collaborative Study Group.The Effect of Angiotensin-Converting-Enzyme Inhibition on Diabetic Nephropathy . N Engl J Med1993;329;1456-62.
13.
Ravid M., Lang R., Rachmani R. et al. Long-term renoprotective effect of angiotensin-converting enzyme inhibition in non-insulin-dependent diabetes mellitus: a 7 year follow-up study. Arch Intern Med1996;156:286-9.
14.
Parving HH, Lehnert H., Brochner-Mortensen J. et al. The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes. N Engl J Med2001;345:870-8.
15.
Brenner BM, Cooper ME, de Zeeuw D. et al. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med2001;345:861-9.
16.
Rossing P., Hommel E., Smidt UM et al. Reduction in albuminuria predicts a beneficial effect on diminishing the progression of human diabetic nephropathy during antihypertensive treatment . Diabetologia1994;37: 511-16.
17.
American Diabetes Association: clinical practice recommendation 2004. Diabetes Care2004;27(suppl 1):S1-S150.
18.
Gerstein HC , Yusuf S., Mann JFE et al. for the Heart Outcomes Prevention Evaluation (HOPE) Study Investigators.Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: results of the HOPE study and MICRO-HOPE sub study. Lancet2000;355;253-9.
19.
Garg R., Yusuf S., for the Collaborative Group on ACE Inhibitor Trials. Overview of randomized trials of angiotensin-converting enzyme inhibitors on mortality and morbidity in patients with heart failure. JAMA1995;273:1450-6.
20.
Cohn JN, Tognoni G., for the Val-HeFT Investigators.Effects of the angiotensin receptor blocker valsartan on morbidity and mortality in heart failure: The Valsartan Heart Failure Trial (Val-HeFT). Circulation2000 ;267:2672-6.
21.
Dahlöf B., Devereux RB, Kjeldsen SE et al. for the LIFE study group.Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol . Lancet2002;359:995-1003.
22.
Pfeffer MA, Swedberg K., Granger CB et al. Effects of candesartan on mortality and morbidity in patients with chronic heart failure: the CHARM-Overall programme. Lancet2003;362:759-66.
23.
van den Meiracker AH, Man in 't Veld AJ, Admiraal PJ et al. Partial escape of angiotensin converting enzyme (ACE) inhibition during prolonged ACE inhibitor treatment: does it exist and does it affect the antihypertensive response?J Hypertens1992;10:803-12.
24.
Balcells E. , Meng QC, Johnson WH Jr et al. Angiotensin II formation from ACE and chymase in human and animal hearts: methods and species considerations . Am J Physiol1997;273:H1769-H1774.
25.
Ohishi M., Ueda M., Rakugi H. et al. Upregulation of angiotensin-converting enzyme during the healing process after injury at the site of percutaneous transluminal coronary angioplasty in humans. Circulation1997; 96:3328-37.
26.
Cao Z., Bonnet F., Candido R. et al. Angiotensin type 2 receptor antagonism confers renal protection in a rat model of progressive renal injury. J Am Soc Nephrol2002;13:1773-87.
27.
Nickenig G. , Baumer AT, Temur Y. et al. Statin-sensitive dysregulated AT1 receptor function and density in hypercholesterolemic men . Circulation1999;100:2131-4.
28.
Mogensen CE , Neldam S., Tikkanen I. et al. Randomised controlled trial of dual blockade of renin-angiotensin system in patients with hypertension, microalbuminuria, and non-insulin dependent diabetes: the candesartan and lisinopril microalbuminuria (CALM) study. BMJ2000;321:1440-4. 29. Jacobsen P., Andersen S., Rossing K. et al. Dual blockade of the renin-angiotensin system in type 1 patients with diabetic nephropathy . Nephrol Dial Transplant2002;17:1019-24.
29.
Jacobsen P. , Andersen S., Rossing K. et al. Dual blockade of the renin-angiotensin system versus maximal recommended doses of ACE inhibition in diabetic nephropathy . Kidney International2003;63:1874-80.
30.
Rossing K., Jacobson P., Pietraszek L. et al. Renoprotective effects of adding angiotensin II receptor blocker to maximal recommended doses of ACE inhibitor in diabetic nephropathy: A randomized double-blind crossover trial. Diabetes Care2003;26:2268-74.
31.
Rossing K., Christensen PK, Parving HHDual blockade of the renin-angiotensin system in diabetic nephropathy: a randomized double-blind crossover study. Diabetes Care2002;25:95-100.
32.
Andersen NH, Poulsen PL, Knudsen ST et al. Long-term dual blockade with candesartan and lisinopril in hypertensive patients with diabetes: The CALM II study. Diabetes Care2005;28:273-7.
33.
Palmer BFManaging hyperkalaemia caused by inhibitors of the renin-angiotensin-aldosterone system. N Engl J Med2004;351:585-92. 35. Ahuja TS, Freeman D., Mahnken JD et al. Predictors of the development of hyperkalemia in patients using angiotensin-converting enzyme inhibitors. Am J Nephrol2000;20:268-73.
34.
Reardon LC, Macpherson DSHyperkalaemia in outpatients using angiotensin converting enzyme inhibitors . Arch Int Med1998;158;26-32.
35.
Nicholls AJThe impact of atherosclerotic renovascular disease on diabetic renal failure. Diabet Med2002 ;19:889-4.
36.
Bonnet F., Thivole CHReversible hyperkalemia at the initiation of ACE inhibitors in a young diabetic patient with latent hyporeninemic hypoaldosteronism (letter). Diabetes Care1996;19:81.
37.
Ruilope LM, Aldigier JC, Ponticelli C. et al. on behalf of the European Group for the Investigation of Valsartan in Chronic Renal Disease. Safety of the combination of valsartan and benazepril in patients with chronic renal disease. J Hypertension2000;18:89-95.
38.
Struthers ADAldosterone: cardiovascular assault. Am Heart J2002; 144:S2-S7.
39.
Rachmani R. , Slavachevsky I., Amit M. et al. The effect of spironolactone, cilazapril and their combination on albuminuria in patients with hypertension and diabetic nephropathy is independent of blood pressure reduction: a randomised controlled study. Diabet Med2004;21:471-5.
40.
Sato A., Hayashi K., Naruse M. et al. Effectiveness of aldosterone blockade in patients with diabetic nephropathy. Hypertension2003;41:64-8.
41.
Krum H., Nolly H., Workman D. et al. Efficacy of eplerenone added to renin-angiotensin blockade in hypertensive patients. Hypertension2002; 40:117-23.
42.
Epstein M., Buckalew V., Altamirano J. et al. Eplerenone reduces proteinuria in type II diabetes mellitus: implications for aldosterone involvement in the pathogenesis of renal dysfunction . J Am Coll Cardiol2002; 39(suppl A):249A.Abstract.
